Abstract
Purpose
This study aimed to compare the measurement properties of EQ-5D-3L(3L) and EQ-5D-5L(5L) in patients with acute myeloid leukemia (AML) in China.
Methods
We consecutively recruited 168 patients with AML from three tertiary hospitals to complete two rounds of interviews using the two versions of the EQ-5D. We compared (i) the ceiling effect using the McNemar’s test, (ii) test–retest reliability using intraclass correlation coefficient (ICC) and Cohen’s weighted Kappa, (iii) convergent validity using Spearman’s rank correlation coefficient (r) and iv) discriminatory ability using F statistic and area under the receiver operating characteristics curve (AUROC) of the 5L and the 3L.
Results
The 5L descriptive system showed significantly lower ceiling effects in comparison to the 3L descriptive system (p < 0.001). While 5L showed superior reproducibility (Cohen’s weighted Kappa = 0.56–0.67 and ICC = 0.89), both instruments exhibited good test–retest reliability. Even though both 3L and 5L showed good convergent and known-groups validity, 5L showed better convergent validity and discriminatory ability.
Conclusion
The current study found both 3L and 5L to be suitable for use in AML patients. However, 5L showed superior measurement properties compared to 3L. Thus, 5L could be the preferred instrument over 3L for use in AML patients.
Similar content being viewed by others
References
Devlin, N. J., & Brooks, R. (2017 Apr). EQ-5D and the EuroQol group: past, present and future. Applied Health Economics and Health Policy, 15(2), 127–137.
Brooks, R. J. (1996). EuroQol: the current state of play. Healthy Policy, 37(1), 53–72.
Group TE. (1990). EuroQol—a new facility for the measurement of health-related quality of life. Health Policy, 36, 199–208.
https://euroqol.org/eq-5d-instruments/eq-5d-3l-about/ TioE-D-LAo.
https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/ TioE-D-LAo.
Pattanaphesaj, J., & Thavorncharoensap, M. J. H. (2015). Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients. Health and Quality of Life Outcomes, 13(1), 14.
Scalone, L., Ciampichini, R., Fagiuoli, S., Gardini, I., Fusco, F., Gaeta, L., et al. (2013). Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases. Quality of Life Research, 22(7), 1707–1716.
Golicki, D., Niewada, M., Karlińska, A., Buczek, J., Kobayashi, A., Janssen, M. F., et al. (2014). Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients. Quality of Life Research, 24(6), 1555–1263.
Poór, A. K., Rencz, F., Brodszky, V., Gulácsi, L., Beretzky, Z., Hidvégi, B., et al. (2016). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Value in Health, 19(7), A572–A573.
Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., et al. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727–1236.
Pickard, A. S., De Leon, M. C., Kohlmann, T., Cella, D., & Sarah, M. C. (2007). Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Rosenbloom, 45(3), 259–263.
Kim, S. H., Kim, H. J., Lee, S. I., & Jo, M. W. (2012). Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea. Quality of Life Research, 21(6), 1065–1073.
Cheng, M. J., Hourigan, C. S., & Smith, T. J. (2014). Adult acute myeloid leukemia long-term survivors. Journal of Leukemia (Los Angel), 2, 2.
van Dongen-Leunis, A., Redekop, W. K., & Uyl-de Groot, C. A. (2016). Which questionnaire should be used to measure quality-of-life utilities in patients with acute leukemia? An evaluation of the validity and interpretability of the EQ-5D-5L and preference-based questionnaires derived from the EORTC QLQ-C30. Value Health., 19(6), 834–843.
Liu, G. G., Wu, H., Li, M., Chen, G., & Nan, L. J. (2014). Chinese time trade-off values for EQ-5D health states. Value in Health, 17(5), 597–604.
Luo, N., Liu, G., Li, M., Guan, H., Jin, X., & Rand-Hendriksen, K. (2017 Apr). Estimating an EQ-5D-5L value set for China. Value Health, 20(4), 662–669.
Fairclough, D. L., & Cella, D. F. (1996). Functional Assessment of Cancer Therapy (FACT-G): Non-response to individual questions. Quality of Life Research, 5(3), 321–329.
Yu, C. L., Fielding, R., Chan, C. L., Tse, V. K., Choi, P. H., Lau, W. H., et al. (2015). Measuring quality of life of Chinese cancer patients: A validation of the Chinese version of the Functional Assessment of Cancer Therapy-General (FACT-G) scale. Multicenter Study, 88(7), 1715–1727.
Wan, C., Meng, Q., Tang, X., Zhang, C., Luo, J., & Zhang, X. (2006). Validation of cancer patient quality of life measurement scale FACT-G Chinese version. Journal of Practical Oncology, 21(1), 77–80.
Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica, 67(6), 361–370.
Marziliano, A., Pessin, H., Rosenfeld, B., & Breitbart, W. (2018). Measuring cohesion and self-disclosure in psychotherapy groups for patients with advanced cancer: An analysis of the psychometric properties of the group therapy experience scale. International Journal of Group Psychotherapy, 68(3), 407–427.
Xiao, S. Y. (1994). The theoretical basis and research applications of “Social Support Rating Scale”. The Journal of Clinical Psychiatry, 4(2), 98–100.
Li, L., Liu, C., Cai, X., Yu, H., Zeng, X., Sui, M., et al. (2019 May 30). Validity and reliability of the EQ-5D-5 L in family caregivers of leukemia patients. BMC Cancer, 19(1), 522.
Flowers, C., Pashos, C. L., Weiss, M. A., Lamanna, N., Farber, C. M., Kipps, T. J., et al. (2011). Variation in health-related quality of life (HRQOL) by ECOG performance status (PS) and fatigue among patients with chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.30.15_suppl.6122.
Efficace, F., Rosti, G., Aaronson, N., Cottone, F., Angelucci, E., Molica, S., et al. (2014 Apr). Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica, 99(4), 788–793.
Terwee, C. B., Bot, S. D., de Boer, M. R., van der Windt, D. A., Knol, D. L., Dekker, J., et al. (2007 Jan). Quality criteria were proposed for measurement properties of health status questionnaires. Journal of Clinical Epidemiology, 60(1), 34–42.
Janssen, M. F., Birnie, E., Haagsma, J. A., & Bonsel, G. J. (2008). Comparing the standard EQ-5D three-level system with a five-level version. Value Health, 11(2), 275–284.
Cohen, J. (2013). Statistical power analysis for the behavioral sciences. London: Routledge.
Yfantopoulos, J. N., & Chantzaras, A. E. (2017 May). Validation and comparison of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in Greece. The European Journal of Health Economics, 18(4), 519–531.
Janssen, M. F., Bonsel, G. J., & Luo, N. (2018 Jun). Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries. Pharmacoeconomics., 36(6), 675–697.
Vickrey, B. G., Hays, R. D., Genovese, B. J., Myers, L. W., & Ellison, G. W. (1997). Comparison of a generic to disease-targeted health-related quality-of-life measures for multiple sclerosis. Journal of Clinical Epidemiology, 50(5), 557–569.
Pickard, A. S., Ray, S., Ganguli, A., & Cella, D. (2012). Comparison of FACT- and EQ-5D-based utility scores in cancer. Value Health, 15(2), 305–311.
Huang, I. C., Willke, R. J., Atkinson, M. J., Lenderking, W. R., Frangakis, C., & Wu, A. W. (2007). US and UK versions of the EQ-5D preference weights: does choice of preference weights make a difference? Quality of Life Research, 16(6), 1065–1072.
Hays, R. D., Anderson, R., & Revicki, D. (1993). Psychometric considerations in evaluating health-related quality of life measures. Quality of Life Research., 2(6), 441–449.
Petrou, S., Morrell, J., & Spiby, H. (2009 May). Assessing the empirical validity of alternative multi-attribute utility measures in the maternity context. Health Qual Life Outcomes., 6(7), 40.
Petrou, S., & Hockley, C. (2005 Nov). An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. Health Economics, 14(11), 1169–1189.
Landis, J. R., & Koch, G. G. (1977). The measurement of observer agreement for categorical data. Biometrics, 33(1), 159–174.
Rajmil LJJoE, Health C. Health measurement scales. A practical guide to their development and use, 3rd ed. 2015;47(5):484.e1-.e1.
Schwenkglenks, M., & Matter-Walstra, K. (2016). Is the EQ-5D suitable for use in oncology? An overview of the literature and recent developments. Expert Review of Pharmacoeconomics & Outcomes Research, 16(2), 207–219.
Lang, H. C., Chuang, L., Shun, S. C., Hsieh, C. L., & Lan, C.-F. (2010). Validation of EQ-5D in patients with cervical cancer in Taiwan. Supportive Care in Cancer, 18(10), 1279–1286.
Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., et al. (2013 Sep). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Quality of Life Research, 22(7), 1717–1727.
Acknowledgements
We are especially grateful to the study participants who have suffered from leukemia and have never given up. We also acknowledge the interviewers for helping with the data collection.
Funding
This work was supported by the National Social Science Foundation of China (Grant No. 71974048, 71503062) and by the China Medical Board (CMB-19–308).
Author information
Authors and Affiliations
Author notes
Hongjuan Yu, Xueyun Zeng and Mingjie Sui contributed equally to this article. They are co-first authors.
Contributions
HY, XZ, MS and RL drafted the manuscript and performed the data analysis. JY, CL and JX collected the data and interpreted the results. WH, HY and HY contributed to study design as well as drafting and editing of the manuscript. RLYT and NL contributed to the reviewing and editing of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
NL is a member of the EuroQol group. All other authors declare no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards and were approved by the Regional Ethical Committee, Harbin Medical University (Project Identification Code: HMUIRB2014012).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yu, H., Zeng, X., Sui, M. et al. A head-to-head comparison of measurement properties of the EQ-5D-3L and EQ-5D-5L in acute myeloid leukemia patients. Qual Life Res 30, 855–866 (2021). https://doi.org/10.1007/s11136-020-02644-w
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11136-020-02644-w